Duration of Immunity to Canine Vaccines:
What We Know and Don't Know
Ronald D. Schultz, Professor and Chair
Department of Pathobiological Sciences
School of Veterinary Medicine, University of Wisconsin-Madison
It has been common practice since the development of canine vaccines in the late 1950's to administer them annually.
The recommendation to vaccinate annually was based on the assumption that immunity would wane in some dogs, thus
to ensure immunity in the population, all dogs required revaccination since it was not practical to test each animal for
antibody. Little or no research has been done to demonstrate that the practice of annual revaccination has any scientific
value in providing greater immunity than would be present if an animal was never revaccinated or was revaccinated at
intervals longer than one year.
In 1978 we recommended an ideal vaccination program would be one in which dogs and cats would be revaccinated at
one year of age and then every third year thereafter (1). That recommendation was based on a general knowledge of
vaccinal immunity, especially the importance of immunologic memory and on duration of protection after natural subclinical
or clinical infections as well as on limited studies we had performed with certain canine and feline vaccines. Since the mid
1970's we have done a variety of studies with various canine vaccines to demonstrate their duration of immunity. From
our studies it is apparent, at least to me, that the duration of immunity for the four most important canine vaccines (core
vaccines) that the duration of immunity is considerably longer than one year. Furthermore, we have found that annual
revaccination, with the vaccines that provide long term immunity, provides no demonstrable benefit and may increase the
risk for adverse reactions. We have assessed duration of protective immunity primarily by two procedures; the first is held
to be the "gold standard and that is to challenge the vaccinated animal with the virulent organism, the second method is
to measure antibody and compare the antibody titer to that which is known to prevent infection (e.g. provide sterile
immunity). The studies we report here include challenge studies as well as studies that determine antibody titers. A
summary of our results show the following (Table 1).